| Position | Action |
|---|---|
| Confirmed 50 SMA retest at $247.73 with RSI > 45 | Add initial 2-3% position |
| 200 SMA test at $226.49 with MACD cross confirmation | Scale to 5% total position |
JNJ's $5.5B talc settlement removes its biggest legal overhang, enabling multiple expansion from a litigation discount to its historical 22-24x forward P/E, while forward EPS inflects 43% from $8.61 TTM to $12.31 consensus.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | 257.79 | neutral |
| 50 SMA | 247.73 | bullish |
| 200 SMA | 226.49 | bullish |
| RSI (14) | 55.49 | bullish |
| MACD | 2.41 | bearish |
| MACD Signal | 3.28 | — |
| MACD Histogram | -0.87 | bearish |
| Bollinger Upper Band | 267.83 | — |
| Bollinger Middle Band | 256.65 | — |
| Bollinger Lower Band | 245.46 | — |
| ATR (14) | 6.14 | — |
| Bandwidth | 22.4 | — |
Support: 245.46 · 247.73 · 256.65 · 226.49 | Resistance: 267.83 · 274.9
JNJ displays textbook bullish alignment across all timeframes with price (259.24) above 10 EMA (257.79), 50 SMA (247.73), and 200 SMA (226.49), all with upward slopes. The stock completed a powerful rally from late June to late July (high 274.90) followed by a healthy 8.9% pullback to 250.44, holding the 10 EMA/Bollinger middle band confluence. Short-term momentum has cooled with MACD bearish cross (histogram -0.87) and ATR expanded to 6.14, suggesting choppy conditions, but RSI reset to neutral (55.49) and MACD remains positive, indicating the bullish thesis is intact rather than broken. Trade bias is BUY on pullbacks toward 256.65-247.73 with stop below 245.46 and targets at 267.83 and 274.90.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Maintain JNJ exposure; structural thesis intact but substantially priced in after 60% rally, entry discipline enforced
HOLD is the appropriate action because the structural bull case (talc settlement de-risking, diversified immunology pipeline, AAA cash flow, 63-year dividend growth) is real but substantially priced in after the 60% rally from lows to $274.90, while the technical deterioration (MACD at -0.87 with line at +2.41, RSI cooling from 74 to 55, ATR +40% since early June, 8.9% pullback from $274.90 to $250.44) provides unambiguous confirmation that aggressive entry would violate risk mandate. Fair value at 22-23x forward EPS implies only 5-8% upside from $259 to $270, with asymmetric downside risk to $226 (12-15% decline) on 200 SMA test, creating unfavorable risk/reward that patience and disciplined re-engagement triggers will resolve. The dividend yield (~2.1%) provides reasonable carry while awaiting the setup to develop.
When: 200 SMA test at $226.49 with MACD cross confirmation
Then: Scale to 5%
TTM EPS is artificially depressed by talc charges; forward earnings show a 43% inflecting jump that makes the forward P/E attractive
↩ rebuts: “Bear's claim that 53% one-year total shareholder return makes the stock overvalued”
· concedes: Stock has had a 53% one-year total shareholder return; MACD has crossed below the signal line (though not the zero axis); Leadership transition at Innovative Medicine creates some uncertainty; Stock is not being recommended to chase at $274; Forward EPS consensus at $12.31 may not fully account for all risks
JNJ's rally has already priced in its biggest catalyst at a premium multiple, leaving limited upside and meaningful downside risks from momentum breakdown, biosimilar erosion, leverage buildup, and leadership transition uncertainty.
· concedes: Pre-reserved talc liability (settlement was telegraphed); Forward EPS consensus is a legitimate analyst estimate (even if potentially optimistic); Leadership transition could prove to be a discount window with hindsight; Technical pullback from $274.90 to $250.44 was orderly (momentum hasn't fully broken)
→ vs conservative: Historical 16-18x P/E multiple anchored outdated; range included massive talc uncertainty that is now permanently removed, requiring structural re-rating ceiling upward
→ vs conservative: Using net debt doubling and negative tangible book as balance sheet concerns ignores AAA-grade cash flow quality, $19B annual FCF, and structurally normal IP-heavy leverage metrics
→ vs neutral: 21x forward P/E treated as static premium rather than re-rating event following $5.5B talc settlement cap removing multi-decade tail risk
→ vs neutral: MACD bearish cross at +2.41 misinterpreted as distribution signal; positive histogram turned negative from cooling momentum, not trend break
→ vs neutral: Stelara biosimilar cliff cited as major concern while underweighting Tremfya, Darzalex, Carvykti, and Caplyta MDD growth drivers offsetting single-product headwind
→ vs neutral: Sector read-through completely missed: Genmab raised guidance on Darzalex royalties, Halozyme beat and raised, Royalty Pharma raised for second consecutive quarter
→ vs neutral: Recession risk premium in defensives should compress given 8% recession probability; defensive names typically re-rate higher when macro fears recede
Market Cap
$624.74B
P/E (TTM)
30.11x
Forward P/E
21.06x
PEG Ratio
4.24
P/B
7.35x
EPS (TTM)
$8.61
Forward EPS
$12.31
Dividend Yield
2.09%
Beta
0.231
52-Week Range
$170.39 – $274.90
50-Day Avg
$245.70
200-Day Avg
$226.75
Revenue (2025)
$94,193M
Gross Profit (2025)
$63,937M
Operating Income (2025)
$25,596M
EBITDA (2025)
$41,055M
Net Income (2025)
$26,804M
Diluted EPS (2025)
$11.03
Gross Margin
67.9%
Operating Margin
27.2%
Net Margin
28.5%
Revenue (TTM)
$97,929M
Total Assets
$199,210M
Total Equity
$81,544M
Total Debt
$47,933M
Net Debt
$28,224M
Goodwill + Intangibles
$99,175M
Inventory
$14,191M
Receivables
$21,331M
Cash & ST Investments
$20,102M
Working Capital
$1,498M
Current Ratio
1.089
Operating Cash Flow (2025)
$24,530M
CapEx (2025)
$5,217M
Free Cash Flow (2025)
$19,313M
Dividends Paid (2025)
$12,381M
Share Buybacks (2025)
$5,953M
Net Acquisitions (2025)
$17,541M
Net Debt Issuance (2025)
$9,637M
End Cash (2025)
$19,709M
ROE
25.7%
ROA
8.6%
Debt/Equity
57.7%
FCF (TTM)
$16.9B
Dividend Growth Streak
63 years
Revenue CAGR (2022-2025)
~5.6%
FCF Growth (2022-2025)
+12%
Strengths
Concerns
Johnson & Johnson is a premier blue-chip defensive healthcare conglomerate with two reporting segments post-2023 Kenvue spin-off: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). The 2025 results show strong recovery from 2024 talc-litigation charges, with revenue of $94.2B, net income of $26.8B (+91% YoY), and EPS of $11.03. The company generates $19.3B in annual free cash flow (20% margin) and maintains an elite 25.7% ROE with 63 consecutive years of dividend growth. Balance sheet leverage increased materially in 2025 (Net Debt of $28.2B) due to $17.5B in M&A spend (Shockwave, Intra-Cellular Therapies), but remains investment-grade quality with ~$20B in cash. Valuation is full at 30.1x TTM P/E but appears more reasonable at 21.1x forward P/E given expected EPS expansion to $12.31. Recommendation: HOLD with bias to accumulate on weakness toward $227 (200-day MA).